Video Shorts

1:09

Unpacking the Design of the NCCN Advocacy Academy

3 months ago

Alyssa Schatz, DrPH, MSW

1:30

Pan-RAS Inhibition Opens New Therapeutic Frontiers in Pancreatic Cancer

3 months ago

Tanios S. Bekaii-Saab, MD

0:46

Outlining the Importance of Updated WHO Diagnostic Criteria for AML

3 months ago

Sanam Loghavi, MD

0:52

Understanding Why the FDA Approval of Sonrotoclax for MCL is Important

3 months ago

Tycel Phillips, MD

How Real-World Studies Address Gaps in Randomized Clinical Trial Data in mCRC

1:20

AI-Powered Imaging May Change Early Pancreatic Cancer Detection

3 months ago

Tanios S. Bekaii-Saab, MD

1:50

Expert Insights on FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML

3 months ago

Courtney DiNardo, MD, MSCE(+1 more)

0:42

The Implications of the SATEEN Trial in HER2+ Metastatic Breast Cancer

3 months ago

Kelly E. McCann, MD, PhD

Jeff M. Michalski, MD, MBA, FACR, FASTRO, WashU Medicine

1:26

Tracking the Evolution of Radiopharmaceuticals in Prostate Cancer

3 months ago

Jeff Michalski, MD, MBA, FASTRO

1:47

Managing Mogamulizumab-Associated Rash in CTCL

3 months ago

Brad Haverkos, MD

1:35

Highlighting the Advantages of Proton Therapy

3 months ago

Madhur Garg, MD, MBA, FACR

1:12

Contextualizing the VIKTORIA-1 Trial in Breast Cancer Prior to ASCO 2026

3 months ago

VK Gadi, MD, PhD

1:06

Treatment and Clinical Trial Considerations in Myeloma Subgroups

3 months ago

Rebecca Silbermann, MD, MMS

4:12

OncLive News Roundup for the Week of 5/3

3 months ago

Chris Ryan(+1 more)

1:16

Highlighting the Importance of Raising Bladder Cancer Awareness

3 months ago

Matthew D. Galsky, MD

1:09

Evolving Management of p53-Mutated Mantle Cell Lymphoma

3 months ago

Tycel Phillips, MD

0:55

MANEUVER Trial Supports Integration of Targeted Therapy Into Upfront TGCT Management

3 months ago

R. Lor Randall, MD, FACS

1:45

Discussing the Implications of the SERENA-6 Trial Design

3 months ago

Alexis LeVee, MD

0:54

Addressing Challenges With Anemia Management in Myelofibrosis

3 months ago

Anthony M Hunter, MD

0:52

Breaking Down the Current State of CAR T-Cell Therapies in PCNSL

3 months ago

Ashley Sumrall, MD

0:50

MountainTAP-30 Trial Seeks to Leverage PRMT5 Inhibitor for MTAP-Deleted Pancreatic Cancer

3 months ago

Shubham Pant, MD, MBBS

1:34

Frontline Treatment and Transplant Considerations in Multiple Myeloma

3 months ago

Ajai Chari, MD

2:13

The Pathologist's Role in Breast Cancer Biomarker Testing

3 months ago

Dara S. Ross, MD

1:00

Early RAS Inhibitor Data Signal Rare Momentum in Metastatic Pancreatic Cancer

3 months ago

Shubham Pant, MD, MBBS

1:20

Spotlighting the Nuances of the SERENA-6 Trial Design Following the FDA's ODAC Vote

3 months ago

Pedram Razavi, MD, PhD

Theresa A. Guise, MD, FASBMR, MD Anderson Cancer Center

1:20

Highlighting the Importance of Mentorship for Early-Career Cancer Researchers

3 months ago

Theresa A. Guise, MD, FASBMR

2:12

Navigating JAK Inhibitors and Transplant in Myelofibrosis

3 months ago

Andrew Kuykendall, MD

4:33

OncLive News Roundup for the Week of 4/26

3 months ago

Chris Ryan(+1 more)

1:40

Highlighting Reconstructive Surgery Options in Breast Cancer

3 months ago

Sara Nunnery, MD, MSCI

2:12

Breast Cancer Experts Discuss Emerging Data and Desicions

3 months ago

Sara Nunnery, MD, MSCI(+1 more)

Bradley McGregor, MD, Dana-Farber Cancer Institute

0:54

Examining the Potential Clinical Impact of the STRIKE Trial in RCC

3 months ago

Bradley A. McGregor, MD

Video Shorts

Trending on OncLive

FDA Approves Rituximab Biosimilar for Hematologic Malignancies

Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026

Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC

Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma

Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC